Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...

Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

There aren’t a lot of easy changes the drugmaker can make to right itself quickly. Boosting sales fast enough to lift shares will be hard, and high debts rule out a game-changing acquisition. Get the ...

Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Dozens of over-the-counter acne products had very high levels of the known carcinogen benzene, even when they were taken ...

An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...

Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...

A $13 million grant from Golden LEAF Foundation will fund training equipment at Wilson Community College to support Johnson & ...

The study, of Intellia’s treatment for hereditary angioedema, is the second Phase 3 trial the biotech has begun testing its “in vivo” gene editing medicines.

AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...